Cambridge Investment Research Advisors
DERM icon

Cambridge Investment Research Advisors’s Journey Medical DERM Stock Holding History

Cambridge Investment Research Advisors’s Portfolio DERM Stock Details DERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-338,050
Closed -$1.99M – 3657
2025
Q1 		$1.99M Buy
338,050
+9,938
+3% +$48.9K 0.01% 1349
2024
Q4 		$1.28M Buy
328,112
+13,662
+4% +$74.6K ﹤0.01% 1669
2024
Q3 		$1.78M Buy
314,450
+19,500
+7% +$100K 0.01% 1445
2024
Q2 		$1.66M Buy
+294,950
New +$1.21M 0.01% 1420

Other funds holding DERM

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Cambridge Investment Research Advisors's DERM Position: Q2 2025 in Review

Cambridge Investment Research Advisors sold out of Journey Medical (DERM) in Q2 2025, closing a stake of 338,050 shares — an estimated $1.99M sold.

Cambridge Investment Research Advisors first reported a position in DERM in Q2 2024 and held it in 4 quarters. The position peaked at $1.99M in Q1 2025. 56 funds tracked by Wall St. Rank hold DERM as of Q2 2025.

  • Cambridge Investment Research Advisors reported no remaining Journey Medical position as of Q2 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 338,050 Journey Medical shares in Q2 2025, an estimated $1.99M.
  • Cambridge Investment Research Advisors first reported a position in Journey Medical in Q2 2024 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's Journey Medical position peaked at $1.99M in Q1 2025.
  • 56 funds tracked by Wall St. Rank held Journey Medical as of Q2 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.